Myriad Genetics discontinues part two of GeneSight study; control group deemed unreliable

MYRIAD GENETICS INC

Part one (April 2024) showed 29% drop in all-cause hospitalizations and 39% drop in psychiatric-related hospitalizations 180 days post-GeneSight.
Part two aimed to compare GeneSight patients vs. matched non-GeneSight control; significant baseline disparities made control group non-viable.
Company concluded data comparing the two groups were not reliable and halted the analysis.
GeneSight's causal role in hospitalization reduction remains unconfirmed without a valid control group.
Company plans to publish full part one results in the near future.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.